Literature DB >> 33602907

Syngeneic leukemia models using lentiviral transgenics.

Nurit Keinan1, Ye'ela Scharff1, Oron Goldstein1, Michael Chamo1, Stefan Ilic1, Roi Gazit2.   

Abstract

Animal models are necessary to study cancer and develop treatments. After decades of intensive research, effective treatments are available for only a few types of leukemia, while others are currently incurable. Our goal was to generate novel leukemia models in immunocompetent mice. We had achieved abilities for overexpression of multiple driving oncogenes simultaneously in normal primary cells, which can be transplanted and followed in vivo. Our experiments demonstrated the induction of primary malignant growth. Leukemia lines that model various types of leukemia, such as acute myeloid leukemia (AML) or chronic lymphocytic leukemia (CLL), were passaged robustly in congenic wild-type immunocompetent mice. These novel leukemia lines, which may complement previous models, offer the flexibility to generate tailored models of defined oncogenes of interest. The characterization of our leukemia models in immunocompetent animals can uncover the mechanisms of malignancy progression and offer a unique opportunity to stringently test anti-cancer chemotherapies.

Entities:  

Year:  2021        PMID: 33602907      PMCID: PMC7893004          DOI: 10.1038/s41419-021-03477-2

Source DB:  PubMed          Journal:  Cell Death Dis            Impact factor:   8.469


  57 in total

Review 1.  Acute Lymphoblastic Leukemia in Children.

Authors:  Stephen P Hunger; Charles G Mullighan
Journal:  N Engl J Med       Date:  2015-10-15       Impact factor: 91.245

2.  TGF-β regulated leukemia cell susceptibility against NK targeting through the down-regulation of the CD48 expression.

Authors:  Chin-Han Huang; Yi-Jen Liao; Tzeon-Jye Chiou; Hsin-Ting Huang; Yen-Hsi Lin; Yuh-Ching Twu
Journal:  Immunobiology       Date:  2019-08-09       Impact factor: 3.144

Review 3.  Biology and relevance of human acute myeloid leukemia stem cells.

Authors:  Daniel Thomas; Ravindra Majeti
Journal:  Blood       Date:  2017-02-03       Impact factor: 22.113

Review 4.  Pediatric leukemia: Moving toward more accurate models.

Authors:  Thomas Milan; Hera Canaj; Chloe Villeneuve; Aditi Ghosh; Frédéric Barabé; Sonia Cellot; Brian T Wilhelm
Journal:  Exp Hematol       Date:  2019-05-30       Impact factor: 3.084

Review 5.  Modeling malignancies using induced pluripotent stem cells: from chronic myeloid leukemia to hereditary cancers.

Authors:  Ali Turhan; Adlen Foudi; Jin Wook Hwang; Christophe Desterke; Frank Griscelli; Annelise Bennaceur-Griscelli
Journal:  Exp Hematol       Date:  2019-01-16       Impact factor: 3.084

6.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.

Authors:  Andrei V Krivtsov; David Twomey; Zhaohui Feng; Matthew C Stubbs; Yingzi Wang; Joerg Faber; Jason E Levine; Jing Wang; William C Hahn; D Gary Gilliland; Todd R Golub; Scott A Armstrong
Journal:  Nature       Date:  2006-07-16       Impact factor: 49.962

7.  CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis.

Authors:  Régis Bataille; Catherine Pellat-Deceunynck; Nelly Robillard; Hervé Avet-Loiseau; Jean-Luc Harousseau; Philippe Moreau
Journal:  Leuk Res       Date:  2007-09-04       Impact factor: 3.156

8.  Transcriptome analysis identifies regulators of hematopoietic stem and progenitor cells.

Authors:  Roi Gazit; Brian S Garrison; Tata Nageswara Rao; Tal Shay; James Costello; Jeff Ericson; Francis Kim; James J Collins; Aviv Regev; Amy J Wagers; Derrick J Rossi
Journal:  Stem Cell Reports       Date:  2013-08-15       Impact factor: 7.765

9.  Nanoscale increases in CD2-CD48-mediated intermembrane spacing decrease adhesion and reorganize the immunological synapse.

Authors:  Oren Milstein; Su-Yi Tseng; Toby Starr; Jaime Llodra; Andrea Nans; Mengling Liu; Martin K Wild; P Anton van der Merwe; David L Stokes; Yair Reisner; Michael L Dustin
Journal:  J Biol Chem       Date:  2008-09-30       Impact factor: 5.157

10.  2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48.

Authors:  M H Brown; K Boles; P A van der Merwe; V Kumar; P A Mathew; A N Barclay
Journal:  J Exp Med       Date:  1998-12-07       Impact factor: 14.307

View more
  1 in total

Review 1.  In Vitro and In Vivo Modeling of Normal and Leukemic Bone Marrow Niches: Cellular Senescence Contribution to Leukemia Induction and Progression.

Authors:  Myriam Janeth Salazar-Terreros; Jean-Paul Vernot
Journal:  Int J Mol Sci       Date:  2022-07-01       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.